vs
CARLISLE COMPANIES INC（CSL）与Ventas（VTR）财务数据对比。点击上方公司名可切换其他公司
Ventas的季度营收约是CARLISLE COMPANIES INC的1.6倍（$1.7B vs $1.1B），CARLISLE COMPANIES INC净利率更高（12.1% vs 3.6%，领先8.6%），Ventas同比增速更快（22.0% vs -4.0%），过去两年Ventas的营收复合增速更高（17.5% vs -14.8%）
卡莱尔公司是专业建筑产品供应商，聚焦于提升建筑能效与稳固性，面向商业建筑领域生产销售单层屋面产品、质保系统及配套配件，旗下设有卡莱尔建筑材料、卡莱尔防水技术两大业务板块，产品涵盖防潮材料、屋面防护层等多个品类。
Ventas是一家领先的医疗地产投资信托企业，旗下资产涵盖养老社区、医疗办公楼、生命科学研究设施及康复医疗中心等，主要在北美、英国地区运营，为医疗服务及生命科学机构提供专业物业解决方案。
CSL vs VTR — 直观对比
营收规模更大
VTR
是对方的1.6倍
$1.1B
营收增速更快
VTR
高出26.0%
-4.0%
净利率更高
CSL
高出8.6%
3.6%
两年增速更快
VTR
近两年复合增速
-14.8%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.7B |
| 净利润 | $127.7M | $59.0M |
| 毛利率 | 34.5% | — |
| 营业利润率 | 17.1% | — |
| 净利率 | 12.1% | 3.6% |
| 营收同比 | -4.0% | 22.0% |
| 净利润同比 | -10.9% | 19.0% |
| 每股收益（稀释后） | $3.10 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSLVTR
| Q1 26 | $1.1B | $1.7B | ||
| Q4 25 | $1.1B | $1.6B | ||
| Q3 25 | $1.3B | $1.5B | ||
| Q2 25 | $1.4B | $1.4B | ||
| Q1 25 | $1.1B | $1.4B | ||
| Q4 24 | $1.1B | $1.3B | ||
| Q3 24 | $1.3B | $1.2B | ||
| Q2 24 | $1.5B | $1.2B |
净利润CSLVTR
| Q1 26 | $127.7M | $59.0M | ||
| Q4 25 | $127.4M | $73.0M | ||
| Q3 25 | $214.2M | $68.7M | ||
| Q2 25 | $255.8M | $71.5M | ||
| Q1 25 | $143.3M | $48.4M | ||
| Q4 24 | $162.8M | $58.7M | ||
| Q3 24 | $244.3M | $21.0M | ||
| Q2 24 | $712.4M | $21.2M |
毛利率CSLVTR
| Q1 26 | 34.5% | — | ||
| Q4 25 | 33.8% | — | ||
| Q3 25 | 36.0% | — | ||
| Q2 25 | 37.3% | — | ||
| Q1 25 | 35.2% | — | ||
| Q4 24 | 36.1% | — | ||
| Q3 24 | 38.6% | — | ||
| Q2 24 | 39.2% | — |
营业利润率CSLVTR
| Q1 26 | 17.1% | — | ||
| Q4 25 | 16.8% | 4.9% | ||
| Q3 25 | 21.8% | 3.0% | ||
| Q2 25 | 23.1% | 3.0% | ||
| Q1 25 | 16.8% | 3.0% | ||
| Q4 24 | 19.9% | -0.0% | ||
| Q3 24 | 23.7% | 1.5% | ||
| Q2 24 | 26.0% | -1.6% |
净利率CSLVTR
| Q1 26 | 12.1% | 3.6% | ||
| Q4 25 | 11.3% | 4.7% | ||
| Q3 25 | 15.9% | 4.6% | ||
| Q2 25 | 17.6% | 5.0% | ||
| Q1 25 | 13.1% | 3.6% | ||
| Q4 24 | 14.5% | 4.6% | ||
| Q3 24 | 18.3% | 1.7% | ||
| Q2 24 | 49.1% | 1.8% |
每股收益（稀释后）CSLVTR
| Q1 26 | $3.10 | — | ||
| Q4 25 | $3.06 | $0.15 | ||
| Q3 25 | $4.98 | $0.14 | ||
| Q2 25 | $5.88 | $0.15 | ||
| Q1 25 | $3.20 | $0.10 | ||
| Q4 24 | $3.76 | $0.13 | ||
| Q3 24 | $5.25 | $0.05 | ||
| Q2 24 | $14.84 | $0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $771.3M | $183.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.7B | $13.2B |
| 总资产 | — | $27.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSLVTR
| Q1 26 | $771.3M | $183.6M | ||
| Q4 25 | $1.1B | $741.1M | ||
| Q3 25 | $1.1B | $188.6M | ||
| Q2 25 | $68.4M | $614.2M | ||
| Q1 25 | $220.2M | $182.3M | ||
| Q4 24 | $753.5M | $897.9M | ||
| Q3 24 | $1.5B | $1.1B | ||
| Q2 24 | $1.7B | $557.1M |
总债务CSLVTR
| Q1 26 | — | — | ||
| Q4 25 | $2.9B | $13.0B | ||
| Q3 25 | $2.9B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $1.9B | $13.5B | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.3B | — |
股东权益CSLVTR
| Q1 26 | $1.7B | $13.2B | ||
| Q4 25 | $1.8B | $12.5B | ||
| Q3 25 | $2.0B | $12.4B | ||
| Q2 25 | $2.1B | $11.5B | ||
| Q1 25 | $2.2B | $11.5B | ||
| Q4 24 | $2.5B | $10.8B | ||
| Q3 24 | $2.8B | $9.8B | ||
| Q2 24 | $3.0B | $9.6B |
总资产CSLVTR
| Q1 26 | — | $27.7B | ||
| Q4 25 | $6.3B | $27.6B | ||
| Q3 25 | $6.5B | $26.9B | ||
| Q2 25 | $5.5B | $26.5B | ||
| Q1 25 | $5.5B | $26.0B | ||
| Q4 24 | $5.8B | $26.2B | ||
| Q3 24 | $6.5B | $25.3B | ||
| Q2 24 | $6.7B | $24.5B |
负债/权益比CSLVTR
| Q1 26 | — | — | ||
| Q4 25 | 1.61× | 1.04× | ||
| Q3 25 | 1.45× | — | ||
| Q2 25 | 0.89× | — | ||
| Q1 25 | 0.87× | — | ||
| Q4 24 | 0.77× | 1.26× | ||
| Q3 24 | 0.83× | — | ||
| Q2 24 | 0.76× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | — |
| 自由现金流经营现金流 - 资本支出 | $-73.0M | — |
| 自由现金流率自由现金流/营收 | -6.9% | — |
| 资本支出强度资本支出/营收 | 2.7% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $924.8M | — |
8季度趋势，按日历期对齐
经营现金流CSLVTR
| Q1 26 | — | — | ||
| Q4 25 | $386.0M | $471.7M | ||
| Q3 25 | $426.9M | $378.6M | ||
| Q2 25 | $287.1M | $475.3M | ||
| Q1 25 | $1.8M | $321.1M | ||
| Q4 24 | $370.6M | $373.6M | ||
| Q3 24 | $312.8M | $353.7M | ||
| Q2 24 | $183.4M | $335.9M |
自由现金流CSLVTR
| Q1 26 | $-73.0M | — | ||
| Q4 25 | $346.1M | — | ||
| Q3 25 | $393.4M | — | ||
| Q2 25 | $258.3M | — | ||
| Q1 25 | $-27.2M | — | ||
| Q4 24 | $334.0M | — | ||
| Q3 24 | $293.5M | — | ||
| Q2 24 | $158.5M | — |
自由现金流率CSLVTR
| Q1 26 | -6.9% | — | ||
| Q4 25 | 30.7% | — | ||
| Q3 25 | 29.2% | — | ||
| Q2 25 | 17.8% | — | ||
| Q1 25 | -2.5% | — | ||
| Q4 24 | 29.7% | — | ||
| Q3 24 | 22.0% | — | ||
| Q2 24 | 10.9% | — |
资本支出强度CSLVTR
| Q1 26 | 2.7% | — | ||
| Q4 25 | 3.5% | — | ||
| Q3 25 | 2.5% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | 3.3% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | 1.7% | — |
现金转化率CSLVTR
| Q1 26 | — | — | ||
| Q4 25 | 3.03× | 6.46× | ||
| Q3 25 | 1.99× | 5.51× | ||
| Q2 25 | 1.12× | 6.65× | ||
| Q1 25 | 0.01× | 6.64× | ||
| Q4 24 | 2.28× | 6.36× | ||
| Q3 24 | 1.28× | 16.84× | ||
| Q2 24 | 0.26× | 15.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSL
暂无分部数据
VTR
| Resident fees and services | $1.3B | 78% |
| Outpatient medical and research portfolio | $230.1M | 14% |
| Triple-net leased properties | $123.1M | 7% |
| Third-party capital management revenues | $4.4M | 0% |
